The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. BeOne Medicines Ltd.'s recent Forms 8-K announced quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in-licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported both option exercises and share sales. On July 14, 2026 he exercised options covering 1,736,800 ordinary shares and sold 145,861 American Depositary Shares at prices between $302.48 and $307.87 per ADS under a Rule 10b5-1 trading plan. After these transactions he holds 5,445,917 ordinary shares directly, additional indirect interests through trusts and a Roth IRA, and 462,866 remaining share options.
BeOne Medicines Ltd. CEO John Oyler exercised options for 60,218 American Depositary Shares at $36.90 and sold 60,218 ADS in open‑market trades in July 2026 at weighted‑average prices between $295.66 and $307.44 under a Rule 10b5‑1 plan, leaving no directly held ADS. The filing also lists 5,605,310 ordinary shares held directly as of July 10, 2026 and additional ordinary shares recorded as indirectly held through various trusts and a Roth IRA, with beneficial ownership disclaimed for several trust positions.
Holders of ONC securities filed notice of a proposed sale of 513,574 ADS through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $156,105,953.04, expected to trade on NASDAQ on July 14, 2026.
The ADS relate to 425,590 ADS from stock options exercised on July 14, 2026, 75,723 ADS from stock options previously exercised on March 3, 2025, and 12,261 ADS from restricted stock units dated June 5, 2026. Separately, 54,885,669 ADS were outstanding; this is a baseline figure, not the amount being sold. Recent 10b5-1 plan sales by John Oyler, the Pan-Oyler Foundation and John V. Oyler covered ADS and common shares on several dates in June and July 2026.
BeOne Medicines Ltd. senior vice president and general counsel Lee Chan Henry reported option exercises and an associated sale of American Depositary Shares (ADSs). On July 8, 2026, he exercised options to acquire multiple blocks of ADSs and sold 664 ADSs at $302.46 per ADS in an open-market transaction pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he held 338,884 Ordinary Shares directly, and continued to hold several option positions over Ordinary Shares with stated exercise prices and future expiration dates.
ONC filed to potentially sell 150,000 ADS on 07/10/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The ADS were acquired via an exercise of stock options for cash from the issuer. In the past three months, reporting person John V. Oyler sold common shares in several transactions, including 3,410 shares for $933,592.21 on 06/23/2026 and 4,940 shares for $1,336,566.40 on 06/08/2026.
ONC received a notice of proposed sale of up to 49,541 ADS to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services on 07/10/2026, with an aggregate market value of $15,002,501.03. The issuer reports 54,885,669 ADS outstanding. The filing also lists recent common share sales by John V. Oyler in June 2026, including 4,940 shares for $1,336,566.40 on June 8 and several smaller transactions later in the month.
BeOne Medicines Ltd. reports the conclusion of a statutory tax audit in China that resulted in a settlement requiring an income tax payment of approximately RMB 446 million, including surcharges and related interest. The payment stems from agreed adjustments to previously filed tax returns and involves no administrative penalty.
The company indicates this income tax payment will be recognized in its U.S. GAAP financial statements for the second quarter of fiscal 2026. The disclosure follows earlier discussion of ongoing international tax audits that may lead to outcomes different from prior estimates because of complex local tax rules.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported a small share disposal tied to tax withholding rather than a discretionary sale. On June 23, 2026, 1,292 American Depositary Shares (ADS) were sold at a weighted average price of $276.2592 per ADS under a mandatory tax withholding provision associated with the vesting of a restricted share unit award.
The restricted share units vest in four equal installments on each anniversary of June 22, 2022, subject to continued service, with potential accelerated vesting upon certain termination events. Following this transaction, Wu holds 12,365 ADS directly, 4,000 ADS indirectly through his spouse, and 1,273,724 ordinary shares directly.
BeOne Medicines Ltd. director and CEO John Oyler reported transactions involving American Depositary Shares (ADSs) tied to his equity compensation. On June 23, 2026, entities associated with him disposed of a total of 3,410 ADSs in open-market sales at weighted average prices between $272.655 and $275.21.
Each ADS represents 13 Ordinary Shares. Footnotes state these sales were effected under a mandatory tax withholding provision in his restricted share unit award agreement upon vesting, rather than as discretionary sales. Following these transactions, Oyler holds 5,605,310 Ordinary Shares directly and additional Ordinary Shares indirectly through various trusts and an LLC, while he disclaims beneficial ownership of certain trust-held securities.
BeOne Medicines Ltd. President and Global Head of R&D Wang Lai reported a small sale of 1,068 American Depositary Shares of the company. The shares were sold at $276.735 per ADS and the transaction is described as an open-market sale.
According to a footnote, this sale was carried out under a mandatory tax withholding provision tied to the vesting of a restricted share unit award that began vesting on June 22, 2022. Each ADS represents 13 ordinary shares.
After these transactions, Wang Lai holds 1,681,004 ordinary shares directly and 601,965 ordinary shares indirectly. Additional RMB Shares are held through structures such as Wang Holdings LLC and an RMB Shares Employee Participation Plan, where he has only indirect economic interest and explicitly disclaims Section 16 beneficial ownership beyond any pecuniary interest.